|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
World Health Organization. IAfRoC:
GLOBOCAN. 2012 http://globocan.iarc.fr/Default.aspx08
18–2016.
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Di Leva G, Garofalo M and Croce CM:
MicroRNAs in cancer. Annu Rev Pathol. 9:287–314. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hausser J and Zavolan M: Identification
and consequences of miRNA-target interactions - beyond repression
of gene expression. Nat Rev Genet. 15:599–612. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Iorio MV, Casalini P, Piovan C, Braccioli
L and Tagliabue E: Breast cancer and microRNAs: Therapeutic impact.
Breast. 20 Suppl 3:S63–S70. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Huang Q, Gumireddy K, Schrier M, le Sage
C, Nagel R, Nair S, Egan DA, Li A, Huang G, Klein-Szanto AJ, et al:
The microRNAs miR-373 and miR-520c promote tumour invasion and
metastasis. Nat Cell Biol. 10:202–210. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen J, Wang BC and Tang JH: Clinical
significance of microRNA-155 expression in human breast cancer. J
Surg Oncol. 106:260–266. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dinami R, Ercolani C, Petti E, Piazza S,
Ciani Y, Sestito R, Sacconi A, Biagioni F, le Sage C, Agami R, et
al: miR-155 drives telomere fragility in human breast cancer by
targeting TRF1. Cancer Res74. 4145–4156. 2014. View Article : Google Scholar
|
|
11
|
Mackiewicz M, Huppi K, Pitt JJ, Dorsey TH,
Ambs S and Caplen NJ: Identification of the receptor tyrosine
kinase AXL in breast cancer as a target for the human miR-34a
microRNA. Breast Cancer Res Treat. 130:663–679. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Piovan C, Palmieri D, Di Leva G, Braccioli
L, Casalini P, Nuovo G, Tortoreto M, Sasso M, Plantamura I, Triulzi
T, et al: Oncosuppressive role of p53-induced miR-205 in triple
negative breast cancer. Mol Oncol. 6:458–472. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bai WD, Ye XM, Zhang MY, Zhu HY, Xi WJ,
Huang X, Zhao J, Gu B, Zheng GX, Yang AG, et al: MiR-200c
suppresses TGF-β signaling and counteracts trastuzumab resistance
and metastasis by targeting ZNF217 and ZEB1 in breast cancer. Int J
Cancer135. 1356–1368. 2014. View Article : Google Scholar
|
|
14
|
Fu J, Xu X, Kang L, Zhou L, Wang S, Lu J,
Cheng L, Fan Z, Yuan B, Tian P, et al: miR-30a suppresses breast
cancer cell proliferation and migration by targeting Eya2. Biochem
Biophys Res Commun. 445:314–319. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li W, Jin X, Zhang Q, Zhang G, Deng X and
Ma L: Decreased expression of miR-204 is associated with poor
prognosis in patients with breast cancer. Int J Clin Exp Pathol.
7:3287–3292. 2014.PubMed/NCBI
|
|
16
|
Wang X, Qiu W, Zhang G, Xu S and Gao Q:
YangZ: MicroRNA-204 targets JAK2 in breast cancer and induces cell
apoptosis through the STAT3/BCl-2/survivin pathway. Int J Clin Exp
Pathol. 8:5017–5025. 2015.PubMed/NCBI
|
|
17
|
Costa RH, Grayson DR and Darnell JE Jr:
Multiple hepatocyte-enriched nuclear factors function in the
regulation of transthyretin and alpha 1-antitrypsin genes. Mol Cell
Biol. 9:1415–1425. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nucera C, Eeckhoute J, Finn S, Carroll JS,
Ligon AH, Priolo C, Fadda G, Toner M, Sheils O, Attard M, et al:
FOXA1 is a potential oncogene in anaplastic thyroid carcinoma. Clin
Cancer Res. 15:3680–3689. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sano M, Aoyagi K, Takahashi H, Kawamura T,
Mabuchi T, Igaki H, Tachimori Y, Kato H, Ochiai A, Honda H, et al:
Forkhead box A1 transcriptional pathway in KRT7-expressing
esophageal squamous cell carcinomas with extensive lymph node
metastasis. Int J Oncol. 36:321–330. 2010.PubMed/NCBI
|
|
20
|
Deutsch L, Wrage M, Koops S, Glatzel M,
Uzunoglu FG, Kutup A, Hinsch A, Sauter G, Izbicki JR, Pantel K, et
al: Opposite roles of FOXA1NKX2-1 in lung cancer progression. Genes
Chromosomes Cancer. 51:618–629. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gerhardt J, Montani M, Wild P, Beer M,
Huber F, Hermanns T, Müntener M and Kristiansen G: FOXA1 promotes
tumor progression in prostate cancer and represents a novel
hallmark of castration-resistant prostate cancer. Am J Pathol.
180:848–861. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu C, Wei Q, Guo J, Zhou JC, Mei J, Jiang
ZN, Shen JG and Wang LB: FOXA1 expression significantly predict
response to chemotherapy in estrogen receptor-positive breast
cancer patients. Ann Surg Oncol. 22:2034–2039. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang Z, Huang L, Shen S, Li J, Lu H, Mo
W, Dang Y, Luo D, Chen G and Feng Z: Sp1 cooperates with Sp3 to
upregulate MALAT1 expression in human hepatocellular carcinoma.
Oncol Rep. 34:2403–2412. 2015.PubMed/NCBI
|
|
24
|
Tu H, Wei G, Cai Q, Chen X, Sun Z, Cheng
C, Zhang L, Feng Y, Zhou H, Zhou B, et al: MicroRNA-212 inhibits
hepatocellular carcinoma cell proliferation and induces apoptosis
by targeting FOXA1. Onco Targets Ther. 8:2227–2235. 2015.PubMed/NCBI
|
|
25
|
Chen G, Kronenberger P, Teugels E, Umelo
IA and De Grève J: Targeting the epidermal growth factor receptor
in non-small cell lung cancer cells: The effect of combining RNA
interference with tyrosine kinase inhibitors or cetuximab. BMC Med.
10:282012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ren H, Zhang P, Tang Y, Wu M and Zhang W:
Forkhead box protein A1 is a prognostic predictor and promotes
tumor growth of gastric cancer. Onco Targets Ther. 8:3029–3039.
2015.PubMed/NCBI
|
|
27
|
Zhang C, Wang L, Wu D, Chen H, Chen Z,
Thomas-Ahner JM, Zynger DL, Eeckhoute J, Yu J, Luo J, et al:
Definition of a FoxA1 cistrome that is crucial for G1 to S-phase
cell-cycle transit in castration-resistant prostate cancer. Cancer
Res. 71:6738–6748. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zheng L, Qian B, Tian D, Tang T, Wan S,
Wang L, Zhu L and Geng X: FOXA1 positively regulates gene
expression by changing gene methylation status in human breast
cancer MCF-7 cells. Int J Clin Exp Pathol. 8:96–106.
2015.PubMed/NCBI
|
|
29
|
DeSantis C, Ma J, Bryan L and Jemal A:
Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guo W, Zhang Y, Zhang Y, Shi Y, Xi J, Fan
H and Xu S: Decreased expression of miR-204 in plasma is associated
with a poor prognosis in patients with non-small cell lung cancer.
Int J Mol Med. 36:1720–1726. 2015.PubMed/NCBI
|
|
31
|
Xia Z, Liu F, Zhang J and Liu L: Decreased
expression of miRNA-204-5p contributes to glioma progression and
promotes glioma cell growth, migration and invasion. PLoS One.
10:e01323992015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sacconi A, Biagioni F, Canu V, Mori F, Di
Benedetto A, Lorenzon L, Ercolani C, Di Agostino S, Cambria AM,
Germoni S, et al: miR-204 targets Bcl-2 expression and enhances
responsiveness of gastric cancer. Cell Death Dis. 3:e4232012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wu ZY, Wang SM, Chen ZH, Huv SX, Huang K,
Huang BJ, Du JL, Huang CM, Peng L, Jian ZX, et al: MiR-204
regulates HMGA2 expression and inhibits cell proliferation in human
thyroid cancer. Cancer Biomark. 15:535–542. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Qiu M, Bao W, Wang J, Yang T, He X, Liao Y
and Wan X: FOXA1 promotes tumor cell proliferation through AR
involving the Notch pathway in endometrial cancer. BMC Cancer.
14:782014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hu Q, Luo Z, Xu T, Zhang JY, Zhu Y, Chen
WX, Zhong SL, Zhao JH and Tang JH: FOXA1: A promising prognostic
marker in breast cancer. Asian Pac J Cancer Prev. 15:11–16. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mehta RJ, Jain RK, Leung S, Choo J,
Nielsen T, Huntsman D, Nakshatri H and Badve S: FOXA1 is an
independent prognostic marker for ER-positive breast cancer. Breast
Cancer Res Treat. 131:881–890. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hisamatsu Y, Tokunaga E, Yamashita N,
Akiyoshi S, Okada S, Nakashima Y, Aishima S, Morita M, Kakeji Y and
Maehara Y: Impact of FOXA1 expression on the prognosis of patients
with hormone receptor-positive breast cancer. Ann Surg Oncol.
19:1145–1152. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Song L, Wei X, Zhang B, Luo X, Liu J, Feng
Y and Xiao X: Role of Foxa1 in regulation of bcl2 expression during
oxidative-stress-induced apoptosis in A549 type II pneumocytes.
Cell Stress Chaperones. 14:417–425. 2009. View Article : Google Scholar : PubMed/NCBI
|
